Objective-To examine select adipokines, including fatty acid-binding protein 4, retinol-binding protein 4, and highmolecular-weight (HMW) adiponectin in relation to cardiovascular disease (CVD) mortality among patients with type 2 diabetes mellitus. Approach and Results-Plasma levels of fatty acid-binding protein 4, retinol-binding protein 4, and HMW adiponectin were measured in 950 men with type 2 diabetes mellitus in the Health Professionals Follow-up Study. After an average of 22 years of follow-up (1993-2015), 580 deaths occurred, of whom 220 died of CVD. After multivariate adjustment for covariates, higher levels of fatty acid-binding protein 4 were significantly associated with a higher CVD mortality: comparing extreme tertiles, the hazard ratio and 95% confidence interval of CVD mortality was 1.78 (1.22-2.59; P trend=0.001). A positive association was also observed for HMW adiponectin: the hazard ratio (95% confidence interval) was 2.07 (1.42-3.06; P trend=0.0002), comparing extreme tertiles, whereas higher retinol-binding protein 4 levels were nonsignificantly associated with a decreased CVD mortality with an hazard ratio (95% confidence interval) of 0.73 (0.50-1.07; P trend=0.09). A Mendelian randomization analysis suggested that the causal relationships of HMW adiponectin and retinol-binding protein 4 would be directionally opposite to those observed based on the biomarkers, although none of the Mendelian randomization associations achieved statistical significance. Conclusions-These data suggest that higher levels of fatty acid-binding protein 4 and HMW adiponectin are associated with elevated CVD mortality among men with type 2 diabetes mellitus. Biological mechanisms underlying these observations deserve elucidation, but the associations of HMW adiponectin may partially reflect altered adipose tissue functionality among patients with type 2 diabetes mellitus. The funding sources had no role in study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the article for publication. The authors are not affiliated with the funding institutions.
T ype 2 diabetes mellitus (T2D) has become a global public health challenge with tremendous social and economic burden. 1 Compared with the nondiabetic population, individuals with T2D have a 2-to 4-fold higher risk of developing cardiovascular disease (CVD), which is the leading cause of death in patients with diabetes mellitus. [2] [3] [4] Although the exact underlying mechanisms are unclear, accumulating evidence indicates that adipokines may be involved in the pathogenesis of CVD and mortality among general populations and patients with diabetes mellitus.
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In particular, fatty acid-binding protein (FABP4; also known as aP2), an adipokine primarily expressed in adipocytes and also in macrophages, [9] [10] [11] [12] [13] plays a pivotal role in co-ordinating and integrating metabolic and inflammatory signaling in the setting of insulin resistance and obesity in mouse models. [14] [15] [16] [17] Moreover, animal experiments have shown that FABP4, when expressed in macrophages, contributes particularly to the cause of atherosclerosis. 18, 19 In addition, epidemiological data supported a positive association between circulating FABP4 levels and the risk of T2D, heart failure, and stroke in the general population. 6, [20] [21] [22] Overall, the accumulating evidence suggests a possible role of FABP4 in the cause of not only diabetes mellitus but also its CVD complications, although few studies have been conducted to evaluate whether FABP4 is associated with CVD mortality among patients with T2D.
Similarly, levels of retinol-binding protein 4 (RBP4), another cytokine primarily produced by adipose tissue, were associated with an elevated risk of developing coronary heart disease among generally healthy population, 7, 23 whereas it is largely unexplored on whether this adipokine predicts CVD mortality among T2D patients. In contrast to the lack of data for FABP4 and RBP4, Menzaghi et al 24 recently reported a positive association between circulating levels of total adiponectin and CVD mortality among T2D patients in 3 prospective cohort studies, especially among men with T2D. The biological mechanisms underlying this positive association are unclear, although this observation suggests that the potentially beneficial effects of high circulating adiponectin, 25 especially high-molecular-weight (HMW) adiponectin, on cardiometabolic risk may not manifest among T2D patients.
To further elucidate associations between these adipokines and CVD mortality among T2D patients, we evaluated prospective relationships between levels of FABP4, RBP4, and HMW adiponectin and CVD mortality among men with T2D in the HPFS study (Health Professionals Follow-up) . We hypothesized that FABP4 and RBP4 levels were positively, whereas HMW adiponectin levels were inversely, associated with CVD mortality in diabetics.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement. Table 1 shows the baseline characteristics of the study population. During 13 103 person-years of follow-up , 220 CVD deaths occurred with an incidence rate of 168/10 000 person-years. Participants with CVD death were older; had a higher prevalence of smoking, hypertension, angina, coronary artery bypass grafting, and myocardial infarction; and were more likely to take aspirin and cholesterol-lowering drugs at baseline. They also had lower levels of estimated glomerular filtration rate, longer diabetes mellitus duration, and higher concentrations of high-sensitivity C-reactive protein, soluble tumor necrosis factor-α receptor 2, FABP4, and HMW adiponectin when compared with the remaining participants (all P<0.05).
Results
The Spearman partial correlations between FABP4, RBP4, HMW adiponectin, body mass index (BMI), and CVD risk markers are shown in Table I in the online-only Data Supplement. In general, of the 3 adipokines, FABP4 was most strongly associated with an adverse profile of CVD risk factors, such as positive correlations with BMI at blood collection, BMI at age 21, triacylglycerol, high-sensitivity C-reactive protein, and soluble tumor necrosis factor-α receptor 2 (r s =0.19-0.40) and inverse correlations with high-density lipoprotein and estimated glomerular filtration rate (r s −0.23 and −0.25, respectively). RBP4 was positively associated with triacylglycerol (r s =0.27) and inversely associated with estimated glomerular filtration rate (r s =−0.31) but not significantly associated with BMI at blood collection or BMI at age 21; HMW adiponectin was positively associated with high-density lipoprotein (r s =0.37) and inversely associated with BMI at blood collection (r s =−0.16) and triacylglycerol (r s =−0.32). Other correlations between adipokines and CVD risk factors were weaker. Between adipokines, FABP4 and RBP4 levels were correlated (r s =0.26), and other correlations were much weaker (r s <0.10).
Elevated FABP4 levels were associated with an elevated CVD mortality (Table 2 ). After multivariate adjustment of covariates, including age, BMI at age 21, physical activity, smoking status, alcohol consumption, diabetes mellitus duration, family history of myocardial infarction, Alternative Healthy Eating Index score, use of aspirin or cholesterol-lowering medication, and baseline morbidity, the hazard ratio and 95% confidence interval of CVD mortality was 1.80 (1.27-2.57; P trend<0.001), comparing extreme tertiles of FABP4. Further adjustment of triacylglycerol, high-density lipoprotein, low-density lipoprotein, estimated glomerular filtration rate, and high-sensitivity C-reactive protein did not change this association materially: the hazard ratio (95% confidence interval) was 1.78 (1.22-2.59; P trend=0.001) for CVD mortality. For RBP4, after multivariate adjustment of the above-mentioned covariates, a nonsignificant, inverse association with CVD mortality was observed (hazard ratio [95% confidence interval] was 0.73 [0.50-1.07]; P trend=0.09). For HMW adiponectin, a positive association was observed in relation to CVD mortality. Comparing men in the lowest tertile of HMW adiponectin, men in the highest tertile had a hazard ratio of 2.07 (1.42-3.06; P trend=0.0002) for CVD mortality after multivariate adjustment. In a secondary analysis, when weight changes (weight change between age 21 and blood collection or weight change between 1986 and blood collection) were further adjusted in models, the results remained similar. Furthermore, when FABP4, RBP4, and HMW adiponectin were mutually adjusted, the results did not change significantly. After excluding participants with myocardial infarction, stroke, angina, or coronary artery bypass grafting at baseline (479 participants), a similar trend was observed, although the associations did not reach statistical significance because of reduced statistical power. After multivariate adjustment, the risk of CVD mortality for the diabetic men in the highest tertile (compared with the lowest tertile) was 1.59 (0.53-4.76) for FABP4 (P trend=0.44), 0.87 (0.64-1.03) for RBP4 (P trend=0.65), and 1.39 (0.54-3.61) for HMW adiponectin (P trend=0.48). In stratified analyses, the associations of plasma FABP4 and HMW adiponectin with risk of CVD mortality remained positive across most of the subgroups defined by age at blood draw, BMI at age 21, and current smoking status, although some of the associations did not reach statistical significance because of diminished statistical power (Table 3 ).
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In the Mendelian randomization analysis, instrumental variables were found for RBP4 and HMW adiponectin, whereas no plausible instrumental variable was available for FABP4 (Table IV in the online-only Data Supplement). We observed an inverse trend of association between HMW adiponectin and CVD mortality (the causal estimate coefficient was −1.9; P=0. 15) , and a positive trend of association between RBP4 and CVD mortality (the causal estimate coefficient was 19.0, P=0.11; Table 4 ), but none of the associations achieved statistical significance.
As secondary analyses, we also examined these adipokines in relation to total and cancer-related mortality. Higher FABP4 and HMW adiponectin levels were associated with an increased all-cause mortality, whereas RBP4 was not significantly associated with all-cause mortality (Table II in the online-only Data Supplement). FABP4 was positively associated with cancer mortality, whereas RBP4 and HMW were not (Table III in the online-only Data Supplement).
Discussion
In this prospective study among US men with T2D, after adjustment of demographics, lifestyle, diet, blood lipids, and inflammatory markers, we found a significant association between elevated levels of FABP4 and increased total and CVD mortality. In contrast, contrary to our hypotheses, higher plasma levels of HMW adiponectin were associated with a higher CVD mortality, and elevated RBP4 levels were nonsignificantly associated with a lower CVD mortality. These associations largely persisted within subgroups defined by various CVD risk factors. To our knowledge, this is among the first investigations that estimated the association of FABP4 with CVD mortality in patients with diabetes mellitus. Previous studies conducted in the general population found that FABP4 might be an early predictor of developing cardiometabolic conditions, including metabolic syndrome and T2D, 20, 26 heart failure, and stroke.
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Another study found that circulating FABP4 predicted the risk of adverse cerebrovascular or cardiovascular events in patients with acute coronary syndrome but not in asymptomatic individuals. 27 The underlying mechanisms linking FABP4 with cardiometabolic conditions are illustrated in animal studies. In obese mice, the use of a small molecular inhibitor of FABP4 or targeted deletion of FABP4 could protect against the development of insulin resistance and lipid dysregulation. 16, 17 Moreover, unlike RBP4 and adiponectin, FABP4 is not only expressed in adipocytes but also in macrophages. In ApoE −/− mice, the deletion of FABP4 genes results in protection from atherosclerosis without significant change in blood lipids or insulin sensitivity. 18, 19 Interestingly, bone-marrow transplantation experiments demonstrated that these effects were solely because of FABP4 expressed in macrophages. 19 These experiments clearly indicate that FABP4 expressed in macrophages causes atherosclerosis through pathways other than insulin resistance. FABP4 is highly expressed in vivo in foam cells of human atherosclerotic plaques. 28 These foam cells, when exposed to oxidized low-density lipoprotein, demonstrated elevated expression levels of FABP4. 28 Expression of FABP4 in macrophages, in turn, significantly increases the triacylglycerol and cholesterol accumulation in the macrophages through downregulation of genes for cholesterol efflux ‡Based on model 2, model 3 was further adjusted for eGFR, triacylglycerol levels (mg/dL), high-density lipoprotein cholesterol (mg/dL), low-density lipoprotein cholesterol (mg/dL), and hsCRP.
and cholesterol ester hydrolysis. 29, 30 Overall, existing evidence from these animal experiments may likely explain the positive association between FABP4 levels and CVD mortality among T2D patients. We also observed a positive association between FABP4 and cancer mortality in this analysis. The mechanisms underlying this observation are unclear, and the role of residual confounding and chance cannot be excluded. On the contrary, several studies demonstrated that elevated expression of FABP4 might be involved in tumor growth and metastasis. [31] [32] [33] The associations for RBP4 and HMW adiponectin observed in the current investigation were not consistent with findings in generally healthy populations. For example, circulating RBP4 levels were positively associated with the risk of diabetes mellitus, coronary heart disease, and other CVD events in the general population. 7, 23, 34 Likewise, in human studies, high adiponectin levels were inversely associated with risk of developing T2D and coronary heart disease. 25, 35, 36 Of note, based on data from previous studies in the HPFS, 24, 35 we also observed that patients with diabetes mellitus had lower total adiponectin levels than healthy controls who were free of CVD and T2D (the median [interquartile range] was 14.1 10.1-19.6] μg/mL versus 16.7 [11.8-22.9 ] μg/mL). Nevertheless, our findings regarding RBP4 and HMW adiponectin were consistent with those in previous studies conducted among some high-risk populations. For example, serum RBP4 levels were significantly associated with reduced mortality in elderly patients with acute exacerbations of chronic obstructive pulmonary disease. 37 Total adiponectin levels predicted mortality or heart failure among elderly participants or patients with carotid atherosclerosis, type 1 diabetes mellitus, and CVD. 8, [38] [39] [40] [41] [42] More recently, in another prospective study consisted of 2094 patients with diabetes mellitus, including the HPFS participants involved in the current analysis, high circulating total adiponectin levels predicted increased CVD mortality in men but not in women. 19 These unexpected observations cannot be explained by evidence from animal studies, suggesting collectively that high RBP4 levels and low adiponectin levels contribute to the cause of obesity, diabetes mellitus, and CVD. 43, 44 These unexpected findings might be explained by potential functional changes of adipose tissue after the development of overt insulin resistance and T2D or the use of diabetes mellitus medication, and thus, these observed associations with mortality may be because of reverse causation bias rendered by existing diseases. For example, a higher prediabetes BMI predicted higher mortality, whereas BMI adjacent to diabetes mellitus diagnosis was no longer associated with excess mortality. 45 Moreover, Nilsson et al 46 demonstrated altered DNA methylation and differential expression of genes related to metabolism and inflammation in adipose tissue from patients with T2D. Tiikkainen et al 47 found that the use of rosiglitazone and metformin could influence hepatic insulin resistance and gene expression in adipose tissue in patients with T2D. Several studies suggested that adiponectin resistance might lead to elevated levels of adiponectin in patients with heart failure, which would in turn predict high CVD mortality. 48, 49 In addition, the natriuretic peptide system including B-type natriuretic peptide (BNP) and the N-terminal fragment of its prohormone (NT-pro BNP) plays an important role in adipose tissue metabolism, 50, 51 which might influence the secretion of adiponectin. Some studies demonstrated that NT-pro BNP and adiponectin had a significantly positive correlation and both could predict a high mortality in participants HR, comparing extreme tertiles, was adjusted for age at blood draw (y), date of blood draw (y), body mass index at age 21 (kg/m 2 ), physical activity (in quintiles), smoking status (never smoked, <10 pack-years, 10-24 pack-years, 25-44 pack-years, 45-64 pack-years, 65+ pack-years, and missing), alcohol consumption (nondrinker, <5.0 g/d, 5.0-9.9 g/d, 10.0-14.9 g/d, 15.0-29.9 g/d, ≥30.0 g/d, and missing), diabetes mellitus duration (y), family history of myocardial infarction, Alternative Healthy Eating Index score (in tertiles), use of aspirin or cholesterol-lowering medication (yes, no), baseline history of hypertension, high cholesterol, angina, coronary artery bypass grafting, myocardial infarction, stroke (yes, no), triacylglycerol levels (mg/dL), high-density lipoprotein cholesterol (mg/dL), low-density lipoprotein cholesterol (mg/dL), and eGFR. Stratifying variables were not included in the model when analyses were stratified by these variables individually. BMI indicates body mass index; CI, confidence interval; eGFR, estimated glomerular filtration rate; FABP4, fatty acid-binding protein 4; HMW, high-molecular-weight; and RBP4, retinol-binding protein 4.
*Data were missing for body mass index at age 21 in 45 participants. †Data were missing for smoking status in 44 participants.
with chronic heart failure or chronic kidney disease. [52] [53] [54] [55] [56] Therefore, another possible explanation was that the positive association between adiponectin and CVD mortality was because of elevated levels of BNP or NT-pro BNP that predispose patients to a higher CVD-related mortality. Clearly, more studies in this regard are needed to further elucidate differential biological pathways linking these adipokines with mortality among healthy population versus populations with existing chronic diseases that may lead to weight change and altered adipose tissue function. The current study has several strengths. This is the first prospective study estimating the associations of plasma FABP4, RBP4, and HMW adiponectin with CVD mortality in men with T2D. Other strengths include a long follow-up period, use of CVD end points validated by medical records or death certificates, and adjustments for a multitude of potential risk factors. There are a few limitations as well. First, the study participants are all male health professions, and most of them are whites. Although our study potentially minimizes residual confounding by socioeconomic status, this relative homogeneity reduces the generalizability to other populations or ethnic groups. Second, we only measured baseline plasma FABP4, RBP4, and HMW adiponectin, which might not represent the long-term levels of these markers. Nonetheless, plasma adipokine levels might remain stable over time. 57 Third, the validity of the ELISA of adiponectin was questioned in a previous study by Blüher et al 58 that reported significant differences between different commercially available assays. Meanwhile, another study among 204 individuals showed that the results of 
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Given our prospective study design, the misclassification of true adiponectin levels is likely to be nondifferential between CVD deaths and the rest of study participants, and thus the true associations are more likely to be biased toward the null. Fourth, we did not collect data on left ventricular ejection fraction, which could impact adiponectin levels, although several previous studies in patients with chronic heart failure suggested that left ventricular ejection fraction might not significantly influence the association of adiponectin with mortality. 53, 60 In addition, we cannot exclude the possibility that these findings are because of chance, especially because we examined 3 adipokines simultaneously. Last, the role of residual confounding could not be entirely ruled out in observational studies.
In conclusion, in this prospective study, elevated levels of FABP4 are associated with higher CVD mortality among men with T2D. The unexpected associations of HMW adiponectin and RBP4 with CVD mortality suggest that the findings about these adipokines in the general population might not directly apply to diseased populations probably because of weight change or alterations of adipose tissue functionality subsequent to disease pathophysiology. Nonetheless, the underlying mechanisms require further exploration.
